

PATIENT NAME : MRS CHOUHAN GARIMA 29001	<b>7 REF. DOCTOR</b> : D	R. BOB PKG
CODE/NAME & ADDRESS : C000138375	ACCESSION NO : 0061WL001632	AGE/SEX : 32 Years Female
	PATIENT ID : MRSCF23129161	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 23/12/2023 12:57:57
NEW DELHI 110030	ABHA NO :	REPORTED :28/12/2023 11:15:06
8800465156		

Results

**Biological Reference Interval** Units

HAEMATOLOGY - CBC				
MEDI WHEEL FULL BODY HEALTH CHECKUP BE	OW 40FEMALE		/	
BLOOD COUNTS, EDTA WHOLE BLOOD				
HEMOGLOBIN (HB)	12.7	12.0 - 15.0	g/dL	
RED BLOOD CELL (RBC) COUNT	5.02 High	3.8 - 4.8	mil/µL	
WHITE BLOOD CELL (WBC) COUNT	8.66	4.0 - 10.0	thou/µL	
PLATELET COUNT	446 High	150 - 410	thou/µL	
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	40.3	36 - 46	%	
MEAN CORPUSCULAR VOLUME (MCV)	80.3 Low	83 - 101	fL	
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	25.3 Low	27.0 - 32.0	pg	
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	31.5	31.5 - 34.5	g/dL	
RED CELL DISTRIBUTION WIDTH (RDW)	13.1	11.6 - 14.0	%	
MENTZER INDEX	16.0			
MEAN PLATELET VOLUME (MPV)	9.1	6.8 - 10.9	fL	
WBC DIFFERENTIAL COUNT				
NEUTROPHILS	54	40 - 80	%	
LYMPHOCYTES	43 High	20 - 40	%	
MONOCYTES	02	2 - 10	%	
EOSINOPHILS	01	1 - 6	%	
BASOPHILS	00	< 1 - 2	%	

Interpretation(s) BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Itisha Dhiman Pathologist



Page 1 Of 16

View Report



**Test Report Status** 



**Biological Reference Interval** Units

PATIENT NAME: MRS CHOUHAN GARIMA 29001	<b>7 REF. DOCTOR</b> : D	R. BOB PKG
CODE/NAME & ADDRESS : C000138375	ACCESSION NO : 0061WL001632	AGE/SEX : 32 Years Female
	PATIENT ID : MRSCF23129161	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 23/12/2023 12:57:57
	ABHA NO :	REPORTED :28/12/2023 11:15:06
8800465156		

Results

	HAEMATOLOGY				
MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE					
ERYTHROCYTE SEDIMENTATION RATE (EBLOOD	ESR),EDTA				
E.S.R METHOD : WESTERGREN METHOD	10	0 - 20	mm at 1 hr		
GLYCOSYLATED HEMOGLOBIN(HBA1C), BLOOD	EDTA WHOLE				
HBA1C	5.6	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 ADA Target: 7.0 Action suggested: > 8.0	%		
ESTIMATED AVERAGE GLUCOSE(EAG)	114.0	< 116.0	mg/dL		

#### Interpretation(s)

**Final** 

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD-**TEST DESCRIPTION** :-Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Estrogen medication, Aging. Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

**Decreased** in: Polycythermia vera, Sickle cell anemia

### LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

**REFERENCE** :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2. Diagnosing diabetes.

Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.



Dr. Itisha Dhiman Pathologist



Page 2 Of 16

View Report





PATIENT NAME : MRS CHOUHAN GARIMA 29001	<b>7 REF. DOCTOR</b> : [	DR. BOB PKG
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : <b>0061WL001632</b> PATIENT ID : MRSCF23129161 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :32 Years Female DRAWN : RECEIVED :23/12/2023 12:57:57 REPORTED :28/12/2023 11:15:06
Test Report Status Final	Results Biological	Reference Interval Units

2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c - 46.7

### HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

 Witamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
 Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
 b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr. Itisha Dhiman Pathologist

**PERFORMED AT :** Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001 Rajasthan, India Tel: 0291-2646000, 2644000, Fax: CIN - U74899PB1995PLC045956 Email : srl.jodhpur@gmail.com

Page 3 Of 16







PATIENT NAME : MRS CHOUHAN GARIMA 29001	<b>7 REF. DOCTOR</b> : [	DR. BOB PKG
	ACCESSION NO : 0061WL001632	AGE/SEX : 32 Years Female
F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : MRSCF23129161 CLIENT PATIENT ID:	DRAWN : RECEIVED : 23/12/2023 12:57:57
NEW DELHI 110030 8800465156	ABHA NO :	REPORTED :28/12/2023 11:15:06

Test Report Status <u>Final</u> Results

**Biological Reference Interval** Units

IMMUNOHAEMATOLOGY			
MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE			
ABO GROUP & RH TYPE, EDTA WHOLE BLOOD			
ABO GROUP METHOD : FORWARD/REVERSE	TYPE B		
RH TYPE METHOD : FORWARD/REVERSE	POSITIVE		

Interpretation(s) ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Itisha Dhiman Pathologist



Page 4 Of 16





Test Report Status



PATIENT NAME: MRS CHOUHAN GARIMA 2900	.7 <b>REF. DOCTOR</b> : D	R. BOB PKG
CODE/NAME & ADDRESS : C000138375	ACCESSION NO : 0061WL001632	AGE/SEX : 32 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : MRSCF23129161	DRAWN :
DELHI		RECEIVED : 23/12/2023 12:57:57
NEW DELHI 110030	ABHA NO :	REPORTED :28/12/2023 11:15:06
8800465156		

<u>Final</u>		

Results

**Biological Reference Interval** Units

BIOCHEMISTRY				
MEDI WHEEL FULL BODY HEALTH CHECKUP BEL	OW 40FEMALE			
GLUCOSE FASTING, FLUORIDE PLASMA				
FBS (FASTING BLOOD SUGAR)	89	Normal : < 100 Pre-diabetes: 100-125 Diabetes: >/=126	mg/dL	
METHOD : SPECTROPHOTOMETRY				
GLUCOSE, POST-PRANDIAL, PLASMA				
PPBS(POST PRANDIAL BLOOD SUGAR) METHOD : SPECTROPHOTOMETRY	93	70 - 140	mg/dL	
LIPID PROFILE WITH CALCULATED LDL				
CHOLESTEROL, TOTAL	240 High	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL	
METHOD : SPECTROPHOTOMETRY	50		<i>.</i>	
TRIGLYCERIDES	59	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/=500 Very High	mg/dL	
METHOD : SPECTROPHOTOMETRY				
HDL CHOLESTEROL	42	< 40 Low >/=60 High	mg/dL	
METHOD : SPECTROPHOTOMETRY			<i></i>	
CHOLESTEROL LDL	186 High	< 100 Optimal 100 - 129 Near optimal/ above optima 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL I	
NON HDL CHOLESTEROL	198 High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL	
VERY LOW DENSITY LIPOPROTEIN	11.8	= 30.0</td <td>mg/dL</td>	mg/dL	

Dr. Itisha Dhiman Pathologist









PATIENT NAME: MRS CHOUHAN GARIMA 290	017	REF. DOCTOR : DR	R. BOB PKG	3	
CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : <b>0061</b> PATIENT ID : MRSC CLIENT PATIENT ID: ABHA NO :	F23129161	DRAWN RECEIVED	:32 Years : :23/12/2023 :28/12/2023	
Test Report Status <u>Final</u>	Results	Biological F	Reference	e Interval I	Jnits

CHOL/HDL RATIO	5.7 High	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk
LDL/HDL RATIO	4.4 High	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk

# Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Category					. asociation of final	
Extreme risk group	A.CAD with > 1 feature of high risk group					
		B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or =				
		50 mg/dl or polyvascular disease				
Very High Risk	1. Establishe	ed ASCVD 2. Diabetes	s with 2 r	najor risk facto	rs or evidence of end	organ damage 3.
	Familial Ho	mozygous Hypercholes	terolemi	a		
High Risk	1. Three ma	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ				
		CKD stage 3B or 4. 4.				
	Artery Calci	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque				
Moderate Risk	2 major AS	2 major ASCVD risk factors				
Low Risk	0-1 major ASCVD risk factors					
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors						
<ol> <li>Age &gt; or = 45 year</li> </ol>	s in males and	l > or = 55 years in fem	ales		garette smoking or to	bacco use
2. Family history of premature ASCVD 4. High blood pressure						
5. Low HDL						
Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.						
Risk Group		Treatment Goals			Consider Drug Th	erapy
	LDL-C (mg/dl) Non-HDL (mg/dl) LDL-C (mg/dl) Non-HDL (mg/dl)					

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.					
Risk Group	Treatment Goals		Consider Drug Therapy		
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)	
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80	
	< OR = 30)	<or 60)<="" =="" td=""><td></td><td></td></or>			
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or></td></or>	<or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or>	> 30	>60	
Very High Risk	<50	<80	>OR= 50	>OR= 80	
High Risk	<70	<100	>OR= 70	>OR-100	
Moderate Risk	<100	<130	>OR=100	>OR= 130	
Low Risk	<100	<130	>OR= 130*	>OR= 160	

Dr. Itisha Dhiman Pathologist

Page 6 Of 16

View Report







PATIENT NAME : MRS CHOUHAN GARIMA 290	017 REF. DOCTOR	C : DR. BOB PKG
CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : <b>0061WL001632</b> PATIENT ID : MRSCF23129161	AGE/SEX : 32 Years Female
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030	CLIENT PATIENT ID: ABHA NO :	RECEIVED :23/12/2023 12:57:57 REPORTED :28/12/2023 11:15:06
8800465156		
Test Report Status Final	Results Biologi	cal Reference Interval Units

\*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL METHOD : SPECTROPHOTOMETRY	0.61	0.2 - 1.0	mg/dL
BILIRUBIN, DIRECT	0.10	0.0 - 0.2	mg/dL
BILIRUBIN, INDIRECT	0.51	0.1 - 1.0	mg/dL
TOTAL PROTEIN METHOD : SPECTROPHOTOMETRY	7.5	6.4 - 8.2	g/dL
ALBUMIN METHOD : SPECTROPHOTOMETRY	3.4	3.4 - 5.0	g/dL
GLOBULIN METHOD : CALCULATED PARAMETER	4.1	2.0 - 4.1	g/dL
ALBUMIN/GLOBULIN RATIO METHOD : CALCULATED PARAMETER	0.8 Low	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT) METHOD : SPECTROPHOTOMETRY	21	15 - 37	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD : SPECTROPHOTOMETRY	34	< 34.0	U/L
ALKALINE PHOSPHATASE METHOD : SPECTROPHOTOMETRY	84	30 - 120	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD : SPECTROPHOTOMETRY	46	5 - 55	U/L
LACTATE DEHYDROGENASE METHOD : SPECTROPHOTOMETRY	158	81 - 234	U/L
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN METHOD : SPECTROPHOTOMETRY	13	6 - 20	mg/dL
CREATININE, SERUM			
CREATININE METHOD : SPECTROPHOTOMETRY	0.64	0.60 - 1.10	mg/dL
BUN/CREAT RATIO			
BUN/CREAT RATIO	20.31 High	5.00 - 15.00	

Dr. Itisha Dhiman Pathologist









			2.24
PATIENT NAME : MRS CHOUHAN GARIMA 2 CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 00	SCF23129161 DRAW RECEI	EX : 32 Years Female
Test Report Status <u>Final</u>	Results	Biological Refer	ence Interval Units
METHOD : SPECTROPHOTOMETRY URIC ACID, SERUM			
URIC ACID METHOD : SPECTROPHOTOMETRY TOTAL PROTEIN, SERUM	2.9	2.6 - 6.0	mg/dL
TOTAL PROTEIN METHOD : SPECTROPHOTOMETRY ALBUMIN, SERUM	7.5	6.4 - 8.2	g/dL
ALBUMIN METHOD : SPECTROPHOTOMETRY	3.4	3.4 - 5.0	g/dL
GLOBULIN GLOBULIN METHOD : CALCULATED PARAMETER	4.1	2.0 - 4.1	g/dL
ELECTROLYTES (NA/K/CL), SERUM SODIUM, SERUM METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY	138	136 - 145	mmol/L
POTASSIUM, SERUM METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY	4.5	3.50 - 5.10	mmol/L
CHLORIDE, SERUM	107	98 - 107	mmol/L

METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY

# Interpretation(s)

Sodium	Potassium	Chloride
Decreased In:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thlazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	Decreased in: Voniting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.

Dr. Itisha Dhiman Pathologist

Page 8 Of 16







PATIENT NAME : MRS CHOUHAN GARIMA 29001	L7 REF. DOCTOR : D	DR. BOB PKG
CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : <b>0061WL001632</b> РАТІЕНТ ID : MRSCF23129161 CLIENT PATIENT ID:	AGE/SEX : 32 Years Female DRAWN : RECEIVED : 23/12/2023 12:57:57
NEW DELHI 110030 8800465156	ABHA NO :	REPORTED :28/12/2023 11:15:06
Test Report Status Final	Results Biological	Reference Interval Units

Increased in: Dehydration	Increased in: Massive hemolysis,	Increased in: Renal failure, nephrotic
excessivesweating, severe	severe tissue damage, rhabdomyolysis,	syndrome, RTA, dehydration,
romiting or diarrhea), diabetes	acidosis, dehydration, renal failure,	overtreatment with
nellitus, diabetesinsipidus,	Addison's disease, RTA type IV,	saline, hyperparathyroidism, diabetes
syperaldosteronism, inadequate	hyperkalemic familial periodic	insipidus, metabolic acidosis from
water intake. Drugs: steroids,	paralysis. Drugs: potassium salts,	diarrhea (Loss of HCO3-), respiratory
icorice,oral contraceptives.	potassium- sparing diuretics,NSAIDs,	alkalosis, hyperadrenocorticism.
	beta-blockers, ACE inhibitors, high-	Drugs: acetazolamide, and rogens,
	dose trimethoprim-sulfamethoxazole.	hydrochlorothiazide, salicylates.
nterferences: Severe lipemia or	Interferences: Hemolysis of sample,	Interferences:Test is helpful in
yperproteinemi, if sodium analysis	delayed separation of serum,	assessing normal and increased anion
nvolves a dilution step can cause	prolonged fist clenching during blood	gap metabolic acidosis and in
purious results. The serum sodium	drawing, and prolonged tourniquet	distinguishing hypercalcemia due to
alls about 1.6 mEq/L for each 100	placement. Very high WBC/PLT counts	hyperparathyroidism (high serum
ng/dL increase in blood glucose.	may cause spurious. Plasma potassium	chloride) from that due to malignancy
	levels are normal.	(Normal serum chloride)

# Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in:Diabetes mellitus, Cushing' s syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease,

sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

**NOTE:** While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin secretion of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

**AST** is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease. **GGT** is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

Dr. Itisha Dhiman Pathologist



Page 9 Of 16

View Report

View Details



PERFORMED AT : Agilus Diagnostics Ltd. M/S S.S. Wellness Centre,Ground Floor,C-22,Shastri Nagar,Near Central Academy School Jodhpur, 342001 Rajasthan, India Tel : 0291-2646000, 2644000, Fax : CIN - U74899PB1995PLC045956 Email : srl.jodhpur@gmail.com



PATIENT NAME: MRS CHOUHAN GARIMA 29001	7 REF. [	DOCTOR : DR. BOB PKG
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : <b>0061WL00</b> PATIENT ID : MRSCF23129 CLIENT PATIENT ID: ABHA NO :	
Test Report Status Final	Results	Biological Reference Interval Units

permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to: Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels-Low Zinc intake,OCP,Multiple Sclerosis TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic

syndrome, Protein-losing enteropathy etc. ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

Dr. Itisha Dhiman Pathologist

**PERFORMED AT :** Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001 Rajasthan, India Tel : 0291-2646000, 2644000, Fax : CIN - U74899PB1995PLC045956 Email : srl.jodhpur@gmail.com

Page 10 Of 16

View Report







PATIENT NAME : MRS CHOUHAN GARIMA 29001	.7 <b>REF. DOCTOR</b> : D	R. BOB PKG
CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : 0061WL001632	AGE/SEX : 32 Years Female
F-703, LADO SARAI, MEHRAULISOUTH WEST		DRAWN : RECEIVED : 23/12/2023 12:57:57
DELHI NEW DELHI 110030		REPORTED :28/12/2023 11:15:06
8800465156		

Test Report	Status	<u>Final</u>
-------------	--------	--------------

Results

**Biological Reference Interval** Units

CLINICAL PATH - URINALYSIS						
MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE						
PHYSICAL EXAMINATION, URINE						
COLOR	PALE YELLOW					
APPEARANCE	SLIGHTLY HAZY					
CHEMICAL EXAMINATION, URINE						
PH	6.0	4.7 - 7.5				
SPECIFIC GRAVITY	1.025	1.003 - 1.035				
PROTEIN	NOT DETECTED	NOT DETECTED				
GLUCOSE	NOT DETECTED	NOT DETECTED				
KETONES	NOT DETECTED	NOT DETECTED				
BLOOD	DETECTED (+)	NOT DETECTED				
BILIRUBIN	NOT DETECTED	NOT DETECTED				
UROBILINOGEN	NORMAL	NORMAL				
NITRITE	NOT DETECTED	NOT DETECTED				
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED				
MICROSCOPIC EXAMINATION, URINE						
RED BLOOD CELLS	10 - 15	NOT DETECTED	/HPF			
PUS CELL (WBC'S)	1-2	0-5	/HPF			
EPITHELIAL CELLS	3-5	0-5	/HPF			
CASTS	NOT DETECTED					
CRYSTALS	NOT DETECTED					
BACTERIA	DETECTED (OCCASIONAL)	NOT DETECTED				
METHOD : MICROSCOPIC EXAMINATION						
YEAST	NOT DETECTED	NOT DETECTED				
Interpretation(s)						

# Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses

Dr. Itisha Dhiman Pathologist



Page 11 Of 16







PATIENT NAME : MRS CHOUHAN GARIMA 29001	<b>7 REF. DOCTOR</b> : [	PR. BOB PKG
CODE/NAME & ADDRESS : C000138375	ACCESSION NO : 0061WL001632	AGE/SEX : 32 Years Female
	PATIENT ID : MRSCF23129161	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 23/12/2023 12:57:57
NEW DELHI 110030	ABHA NO :	REPORTED :28/12/2023 11:15:06
8800465156		

#### Test Report Status <u>Final</u>

Results

**Biological Reference Interval** Units

Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind
	of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr. Itisha Dhiman Pathologist

Page 12 Of 16







PATIENT NAME : MRS CHOUHAN GARIMA 29001	<b>7 REF. DOCTOR</b> : D	DR. BOB PKG
CODE/NAME & ADDRESS : C000138375	ACCESSION NO : 0061WL001632	AGE/SEX : 32 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : MRSCF23129161	DRAWN :
DELHI	CLIENT PATIENT ID:	RECEIVED : 23/12/2023 12:57:57
NEW DELHI 110030	ABHA NO :	REPORTED :28/12/2023 11:15:06
8800465156		
	1	I

Test Report Status Final

Results

**Biological Reference Interval** Units

CYTOLOGY

# MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

# PAPANICOLAOU SMEAR

TEST METHOD

SAMPLE NOT RECEIVED



Dr. Itisha Dhiman Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. M/S S.S. Wellness Centre,Ground Floor,C-22,Shastri Nagar,Near Central Academy School Jodhpur, 342001 Rajasthan, India Tel : 0291-2646000, 2644000, Fax : CIN - U74899PB1995PLC045956 Email : srl.jodhpur@gmail.com Page 13 Of 16

View Report





<u>Final</u>



PATIENT NAME : MRS CHOUHAN GARIMA 29001	7 REF. DOCTOR : D	R. BOB PKG
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : MRSCF23129161 CLIENT PATIENT ID:	AGE/SEX : 32 Years Female DRAWN : RECEIVED : 23/12/2023 12:57:57 REPORTED : 28/12/2023 11:15:06
Test Report Status Final	Results Biological	Reference Interval Units

SPECIALISED	<b>CHEMISTRY</b> -	HORMONE

SPECIALISED CHEMISTRY - HORMONE					
MEDI WHEEL FULL BODY HEALTH CHE	CKUP BELOW 40FEMALE				
THYROID PANEL, SERUM					
ТЗ	99.16	Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester:105.0 - 230.0 2nd Trimester:129.0 - 262.0 3rd Trimester:135.0 - 262.0	ng/dL		
Τ4	5.99	Non-Pregnant Women 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70	µg/dL		
TSH (ULTRASENSITIVE)	1.430	Non Pregnant Women 0.27 - 4.20 Pregnant Women (As per American Thyroid Association 1st Trimester 0.100 - 2.500 2nd Trimester 0.200 - 3.000 3rd Trimester 0.300 - 3.000			

# Interpretation(s)

Triiodothyronine T3 , Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low		<ol> <li>Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) Post Thyroidectomy (4) Post Radio-Iodine treatment</li> </ol>

Dr. Itisha Dhiman Pathologist



View Report

View Details



**PERFORMED AT:** Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001 Rajasthan, India Tel: 0291-2646000, 2644000, Fax: CIN - U74899PB1995PLC045956 Email : srl.jodhpur@gmail.com



PATIENT NAME : MRS CHOUHAN GARIMA 29001	7 REF. DOCTOR : [	DR. BOB PKG
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : <b>0061WL001632</b> PATIENT ID : MRSCF23129161 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :32 Years Female DRAWN : RECEIVED :23/12/2023 12:57:57 REPORTED :28/12/2023 11:15:06
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
		1			hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
		1			inflammation, drugs like amphetamines, lodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	<ol> <li>Secondary and Tertiary Hypothyroidism</li> </ol>
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
		1			hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association duriing pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> \*\*End Of Report\*\* Please visit www.agilusdiagnostics.com for related Test Information for this accession

Dr. Itisha Dhiman Pathologist



Page 15 Of 16







PATIENT NAME: MRS CHOUHAN GARIMA 29001	7 REF. DOCTOR : [	DR. BOB PKG
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : <b>0061WL001632</b> PATIENT ID : MRSCF23129161 CLIENT PATIENT ID: ABHA NO :	AGE/SEX : 32 Years Female DRAWN : RECEIVED : 23/12/2023 12:57:57 REPORTED : 28/12/2023 11:15:06
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

# **CONDITIONS OF LABORATORY TESTING & REPORTING**

1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form. 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.

3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.

### 4. A requested test might not be performed if:

- i. Specimen received is insufficient or inappropriate
- ii. Specimen quality is unsatisfactory
- iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.

Test results may vary based on time of collection, 7. physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

8. Test results cannot be used for Medico legal purposes.

9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

## **Agilus Diagnostics Ltd**

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



Dr. Itisha Dhiman Pathologist

**PERFORMED AT :** Agilus Diagnostics Ltd. M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School Jodhpur, 342001 Rajasthan, India Tel : 0291-2646000, 2644000, Fax : CIN - U74899PB1995PLC045956 Email : srl.jodhpur@gmail.com

Page 16 Of 16



